アントイタヒカルディア・パッシングは,右心室と比較して左心室支部領域に投与された場合,不全性心室短動脈の臨床前モデルにおいてより効果的です
bioRxiv : the preprint server for biology
|September 5, 2025
まとめ
植え付け可能な心臓変容器による左側支部のペースは,従来の右側心房ペースよりも心房短拍の終止に効果的です. この研究は,LBBAのペースを強調しています.
科学分野:
- 心臓の電気生理学
- 医療機器技術
- 臨床前研究
背景:
- 埋め込み式心動脈除細動器 (ICD) による抗心動脈刺激 (ATP) は,心室動脈失速 (VT) を終了させます.
- 左束の枝領域 (LBBA) のペースは,生理学的,同期的な心室活性化を提供します.
- LBBAのリードATPと従来の右心室 (RV) のリードATPを比較することは,治療の最適化に不可欠です.
研究 の 目的:
- LBBA経由で投与されたATPの有効性と安全性を,従来のRV経由と比較する.
- 各ペース戦略に関連する終了率と有害事象を評価する.
- VT終了を成功させるためのアクティベーションシーケンスとペースパルス要件を分析する.
主な方法:
- 誘発性不血症再注血による臨床前動物モデル (n=7) を用いた.
- ICDに接続されたRVアペックスとLBBAにインプラントされたペーシングケーブル
- 誘発性VTエピソード中にRVまたはLBBAに配送されたバストATP,アクティベーションパターンの分析.
主要な成果:
- LBBA ATPは,RV ATP (47. 3%,P=0. 04) と比較して,静脈結末率 (70. 2%) が著しく高かった.
- 静脈動加速や静脈動誘発の有意な差異は認められなかった.
- LBBA ATPはより少ないパルス (4. 1対5. 1ビート,P=0. 04) を必要とし,成功的な静脈経路終結のためにより早いPurkinje活性化を示しました.
結論:
- LBBAのリードATPは,RVのリードATPよりも優れている.
- LBBAペースは,より効率的かつ迅速な心室活性化を促進します.
- これらの発見は,心臓電気療法のためのLBBAリードの採用の増加を支持します.
さらに関連する動画
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
14.9K
05:12Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
3.3K
関連する概念動画
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Disturbances in Heart Rhythm
5.3K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
5.3K
Dysrhythmias IV: Characteristics of Bradyarrhythmias
788
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
788
Dysrhythmias VI: Management of Dysrhythmias
597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597
Cardiopulmonary Resuscitation IV: Pharmacological Management
1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
1.2K
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.2K
